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Poxviruses encode proteins that suppress host im-
mune responses, including secreted decoy receptors for
pro-inflammatory cytokines such as interleukin-1 (IL-1)
and the vaccinia virus proteins A46R and A52R that
inhibit intracellular signaling by members of the IL-1 re-
ceptor (IL-1R) and Toll-like receptor (TLR) family. In vivo,
the TLRs mediate the innate immune response by serving
as pathogen recognition receptors, whose oligomerized
intracellular Toll/IL-1 receptor (TIR) domains can initiate
innate immune signaling. A family of TIR domain-
containing adapter molecules transduces signals from en-
gaged receptors that ultimately activate NF-B and/or in-
terferon regulatory factor 3 (IRF3) to induce pro-
inflammatory cytokines. Data base searches detected a
significant similarity between the N1L protein of vaccinia
virus and A52R, a poxvirus inhibitor of TIR signaling.
Compared with other poxvirus virulence factors, the pox-
virus N1L protein strongly affects virulence in vivo; how-
ever, the precise target of N1L was previously unknown.
Here we show that N1L suppresses NF-B activation fol-
lowing engagement of Toll/IL-1 receptors, tumor necrosis
factor receptors, and lymphotoxin receptors. N1L inhib-
ited receptor-, adapter-, TRAF-, and IKK- and IKK--de-
pendent signaling to NF-B. N1L associated with several
components of the multisubunit I-B kinase complex,
most strongly associating with the kinase, TANK-binding
kinase 1 (TBK1). Together these findings are consistent
with the hypothesis that N1L disrupts signaling to NF-B
by Toll/IL-1Rs and TNF superfamily receptors by target-
ing the IKK complex for inhibition. Furthermore, N1L
inhibited IRF3 signaling, which is also regulated by
TBK1. These studies define a role for N1L as an immuno-
modulator of innate immunity by targeting components
of NF-B and IRF3 signaling pathways.
Vaccinia virus is a poxvirus that was used over 20 years ago
to eradicate variola virus infection (smallpox) (1). The variola
and vaccinia orthopoxviruses express homologs of proteins en-
coded by the immune response genes of their hosts (1). These
homologs include secreted decoy receptors for interleukins 1
and 18 (IL-1 and IL-18)1 (1). Vaccinia also encodes proteins
that inhibit intracellular signaling by the toll-like receptor
family (TLRs) (2). In vivo, the TLRs mediate the innate im-
mune response by serving as pathogen-associated pattern rec-
ognition receptors (3), whose oligomerized intracellular regions
can cluster intracellular Toll/IL-1 receptor (TIR) domains.
Clustering of homotypically associated TIR domain-containing
adapters transduces signals that ultimately activate NF-B
and cytokine response pathways (4). Vaccinia virus encodes the
A46R and A52R proteins, which have been shown to act as
dominant negative inhibitors of TIR signaling. A46R has been
shown to inhibit IL-1 signaling, whereas A52R interferes with
IL-1, IL-18, and TLR signaling, thereby inhibiting both the
innate and ultimately the adaptive immune response (2).
Signals initiated by several pro-inflammatory cytokines, or
by Toll receptor engagement, lead to TIR clustering that re-
cruits one or more TIR adapter proteins: Mal/TIRAP, TRIF/
TICAM-1, MyD88, and TRAM/TIRP/TICAM-2 (5–12). Recruit-
ment of these TIR domain-containing adapter proteins leads to
the recruitment of IRAK family members, which subsequently
activate TRAF6 (13). Activated TRAF6 is thought to autoubiq-
uitinate and then bind and activate a transforming growth
factor- activated kinase 1-containing complex. Transforming
growth factor- activated kinase 1 then likely phosphorylates
and activates the I-B kinase (IKK) complex (14). The IKK
complex is composed of two structurally similar kinases, IKK-
and IKK-, as well as the noncatalytic regulatory subunit
IKK- (also called NEMO). The activated IKK complex phos-
phorylates I-B on serines 32 and 36 leading to its polyubiq-
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uitination and degradation by the proteasome. Degradation of
I-B permits nuclear translocation of NF-B, ultimately driv-
ing transcription of NF-B-responsive genes (reviewed in Refs.
15 and 16). Current data indicate that the IKK complex is
critical for IB degradation and NF-B activation in response
to pro-inflammatory signals.
Vaccinia virus was known to encode two proteins that inhibit
the components of the Toll and IL-1 signaling pathways (2).
Other poxviruses encode several uncharacterized homologs of
these Toll/IL-1R signaling inhibitors (17). We conducted data
base searches that detected a significant similarity among pre-
viously identified poxvirus inhibitors of Toll/IL-1R signaling (2)
and the N1L protein of vaccinia virus. N1L is among the
strongest determinants of vaccinia virus virulence (18, 19).
Whereas N1L has modest effects on adaptive immunity, N1L
suppresses initial host defenses against vaccinia virus chal-
lenge by a factor of 104 (18), suggesting that N1L inhibits
innate immunity. However, the mechanism whereby the N1L
virulence factor functions was previously unknown (18, 19).
Here it is shown that signaling via TNF-, lymphotoxins,
and Toll/IL-1R family members are fundamental immune re-
sponse pathways inhibited by N1L. Signaling by inflammatory
cytokines, TIR adapter molecules, and several downstream
components of the NF-B signaling pathway is inhibited by
N1L. N1L co-immunoprecipitates along with members of the
IKK complex. N1L also inhibited the activation of interferon
regulatory factor 3 (IRF3) in response to double-stranded RNA
stimulation of TLR3 or transfection of a TIR adapter that
mediates signaling to IRF3. Taken together, these findings are
consistent with the hypothesis that N1L disrupts the IRF3/
NF-B signaling pathways by targeting the IKK kinase com-
plex, thereby establishing the role of N1L as a viral immuno-
modulator of innate immunity.
MATERIALS AND METHODS
Cell Culture and Cell Lines—Cells were maintained at 37 °C in a
humidified atmosphere of 5% CO2. HEK 293 cell-stable transfectants
were maintained in Dulbecco’s modified Eagle’s medium in the presence
of 400 g/ml Geneticin sulfate, 10% heat-inactivated bovine calf serum,
600 g/ml L-glutamine, penicillin-streptomycin (Invitrogen), and 20
g/ml ciprofloxacin. Wild type HEK cells were maintained in the iden-
tical medium without Geneticin. The HEK cells stably expressing
CD14, MD2, and either TLR2, TLR3, or TLR4 have been described
previously (6, 20, 21). For use in transfection assays, HEK 293 cells
were typically seeded at 2  104 cells per milliliter in 96-well plates 24 h
prior to transfection.
Vector Construction and Plasmids—An N1L construct was created
by PCR amplification of the N1L open reading frame of vaccinia virus
(Copenhagen strain) DNA donated by Francis Ennis and Masanori
Terajima (University of Massachusetts Medical School, Worcester,
MA). To create N1L-encoding vectors, N1L was amplified using the
primers: 5-ATGAGGACTCTACTTATTAGA-3 and 5-TTATTTTTCA-
CCATATAGATC-3. The PCR product was TA-cloned into pCR3.1 (In-
vitrogen). The resulting construct, pCR3.1N1L, was sequenced in both
directions using bGH reverse and T7 forward primers. N1L cDNA was
subcloned into the pDNR-dual vector, which encodes a C-terminal 6
histidine-arginine (HN) tag (BD Biosciences). pDNRN1L-6HN under-
went recombination with a hemagglutinin (HA)-acceptor vector yield-
ing an HA-N1L-HN-tagged version of N1L. The resulting construct was
also sequenced. pcDNA3.1N1L was constructed by ligating BamHI-
NotI-digested pCR3.1N1L into pcDNA3.1() that had been identically
digested. FLAG-tagged Mal, TRIF, IKK, TBK1, and the pGL3–5XB-
luc plasmid were previously described (6). The ISG54 ISRE luciferase
vector was purchased from Stratagene. (FLAG-tagged TRAM was also
previously described (6).) N-terminally FLAG-tagged IKK- (22), a C-
terminally FLAG-tagged modification of IKK- (23), FLAG-TRAF6, and
FLAG-TRAF2 (24) were gifts of D. Goeddel (Tularik, Inc., San Fran-
cisco, CA). The plasmid encoding BZLF1 was a gift of Joan Mannick
(University of Massachusetts Medical School). The plasmid thymidine
kinase Renilla luciferase (pTk-Renilla) was purchased from Promega
Inc. (Madison, WI). The plasmid encoding MyD88 was from M. Muzio
(Mario Negri Institute, Milan, Italy). Chimeric TLR receptors CD4-
TLR1, CD4-TLR2, CD4-TLR4, and CD4-TLR6, composed of the extra-
cellular domain of CD4 fused to the transmembrane domain and cyto-
solic tail of the TLR, were gifts from R. Medzhitov (Yale University,
New Haven, CT).
Reagents—Poly(dIdC) was purchased from Amersham Biosciences.
The Mycoplasma fermentans-derived membrane macrophage-activat-
ing lipopeptide of 2 kDa was generated as previously described (25) and
was obtained both from P. F. Mühlradt (Gesellschaft für Biotechnolo-
gische Forschung, Braunschweig, Germany) and from G. Rawadi (Insti-
tute Pasteur, Paris, France). Bacterial lipopolysaccharide (LPS) derived
from Escherichia coli strain 011:B4 was purchased from Sigma-Aldrich
and either used directly or purified as described before (26). Human
IL-1- and TNF- were purchased from Cell Sciences (Woburn, MA).
Transient Transfection and NF-B or IRF3 Reporter Assays—HEK
293 cells were transfected with vectors encoding components of either
the TIR or the lymphotoxin signal transduction pathways. HEK cells
were co-transfected with ISRE luciferase vector or NF-B luciferase
vector, Tk-Renilla luciferase vector, N1L or empty vector, and in certain
cases with a component of the NF-B signaling pathway. All HEK 293
cell transfections were performed using GeneJuice (Novagen, Madison,
WI) according to the manufacturer’s recommendations. Transfection
efficiency was normalized by transfection of cells with a plasmid encod-
ing Renilla luciferase. The amount of DNA transfected was equalized
among experiments by the addition of various amounts of the appro-
priate empty vector plasmid. To assay firefly and Renilla luciferase
activity, cells were lysed using passive lysis buffer (Promega), and
luciferase activity was determined by standard protocols, using meth-
ods as described (7). Results are presented as mean  S.E. and are
consistent with the results of at least three separate experiments.
Statistical analyses were via an unpaired, two-tailed t test performed
using GraphPad Prism software.
Co-immunoprecipitation—HEK cells were co-transfected with HA/
HN-tagged N1L and a FLAG-tagged component of the NF-B signal
transduction system, as indicated in the figure legends. For each trans-
fection, a confluent T25 flask of HEK 293 cells was trypsinized and
washed. Cells were then lysed on ice for 1 hour in 100 l of a lysis buffer
comprising 0.5% Nonidet P-40, 300 mM NaCl, 50 mM Tris, pH 7.6, and
CompleteTM protease inhibitor cocktail (Roche Applied Science). Ly-
sates were centrifuged at 4 °C for 20 min at 14,000  g, and lysates
were immunoprecipitated with anti-HN antibody (BD Biosciences)
bound to Protein A-Sepharose beads (Amersham Biosciences). Immu-
noprecipitated proteins were boiled in Laemmli buffer for 5 min and
electrophoresed on a 15% SDS-PAGE gel. Transfer to a 0.45-m PVDF
membrane was followed by blocking, and then the blot was probed with
anti-FLAG monoclonal antibodies (M2, Sigma-Aldrich) and later
probed with a donkey anti-mouse horseradish peroxidase (Amersham
Biosciences) for 30 min essentially as described (27). In certain exper-
iments the primary antibody step was followed by incubation with a
horseradish peroxidase-conjugated antibody that recognizes native rab-
bit IgG (TrueBlotTM, eBioscience, San Diego, CA). Between the blocking
and antibody incubation steps the PVDF membrane was washed re-
peatedly with phosphate-buffered saline/Tween 20. Resulting bands on
the immunoblot were developed with the ECL developer system (Am-
ersham Biosciences) and visualized on a Fuji Imager. Immunoprecipi-
tation with anti-HN-coated Protein A-Sepharose beads followed by im-
munoblot with anti-FLAG antibody was used to confirm the specificity
of the results.
In other experiments, anti-HN antibodies (Clontech) were used to
co-immunoprecipitate HA-TANK and HA-IKK alongside HA-N1L-HN.
Subsequently, an immunoblot with anti-HA antibody (Clontech) was
performed as above. Finally, anti-IKK antibody (Cell Sciences) was
used to immunoblot lysates from the indicated transfectants that were
immunoprecipitated with anti-FLAG antibody. Presence of IKK in
lysates was also confirmed.
In Vitro Transcription and Translation and Protein-Protein Interac-
tion—In vitro transcription and translation were performed essentially
according to the manufacturer’s instructions as outlined in the TNT
Quick kit from Promega (Madison, WI) using 0.5 g of the indicated
DNA template, a biotinylated lysine label (Pathdetect, Promega). After
confirmation of protein expression with an aliquot of protein, aliquots of
N1L and various IKK components were incubated in 20 mM HEPES, pH
7.9, 60 mM NaCl, 1 mM dithiothreitol, 6 mM MgCl2, 8.2% glycerol, and
0.1 mM EDTA and CompleteTM protease inhibitor (Roche Applied Sci-
ence) at 4 °C for 1 h. FLAG-tagged proteins were immunoprecipitated
with Protein G-Sepharose-coupled anti-FLAG antibody, or HA-tagged
proteins were immunoprecipitated with Protein A-Sepharose-coupled
anti-HA antibody and then washed four times in hypotonic lysis buffer
(see above). Samples were then analyzed by SDS-PAGE and blotted


























onto PVDF membranes, which were blocked in phosphate-buffered
saline, 0.05% Tween 20 and subsequently incubated with streptavidin
horseradish peroxidase. Labeled proteins on the blot were detected by
chemiluminescence (Promega), and images were captured on a Fuji
Imager.
RESULTS
The N1L Proteins from Vaccinia and Other Poxviruses Have
Sequence Similarity to Inhibitors of NF-B Signaling—The
amino acid sequence of N1L is relatively conserved from sheep-
pox virus to vaccinia, and N1L amino acid sequence is almost
identical among most vaccinia viruses (19). Vaccinia virus en-
codes two known inhibitors of IL-1 and TLR signaling that are
similar in sequence (2), albeit functionally distinct inhibitors of
NF-B signaling (27). Several poxvirus proteins have been
noted as potential inhibitors of NF-B signaling based upon
their sequence similarity (17, 28) to known poxvirus inhibitors
of NF-B stimulation (2, 27). Our data base searches demon-
strate that N1L is very similar (PHI-BLAST e  3  1012) to
A52R, which has been shown to inhibit Toll, IL-1, and IL-18
signaling to NF-B (2). Because of this sequence similarity, we
hypothesized that N1L inhibited signaling to NF-B.
N1L Inhibits Signaling to NF-B by IL-1, TNF-, and Lym-
photoxins—Because N1L has sequence similarity to poxvirus
inhibitors of signaling by IL-1 and TLRs (2), we first tested the
hypothesis that N1L inhibits IL-1 function. Stimulation of
NF-B activity by IL-1 was significantly suppressed by N1L
(Fig. 1A, p  0.0084). N1L also inhibited stimulation of NF-B
by TNF- signaling (Fig. 1A, p  0.015). Next, the effect of N1L
on stimulation by the lymphotoxin family member, LIGHT
(29), was examined. In a simultaneous experiment (Fig. 1A),
N1L inhibited LIGHT-mediated NF-B signaling 5-fold com-
pared with vector-transfected cells, which was significant (p 
0.02). The finding that N1L also inhibited signaling by TNF-
and LIGHT (Fig. 1A), whereas A52R does not block TNF- (2),
indicated that N1L was a functionally distinct vaccinia virus
inhibitor of signaling to NF-B.
To determine the specificity of the inhibition of NF-B activ-
ity by N1L, the activity of N1L on reporter constructs other
than NF-B was tested. N1L was transfected with one of three
reporter constructs: NF-B luciferase, AP-1 luciferase, or
NFAT luciferase. Reporter constructs were co-transfected with
the Epstein-Barr virus transactivator BZLF1, which both binds
to and stimulates transcription from AP-1 sites (30) while
inhibiting NF-B activity in lymphocytes (31). Despite 2-fold
inhibition of basal NF-B activity, N1L did not inhibit AP-1
luciferase activity (Fig. 1B). BZLF1 suppressed NF-B activity,
consistent with results in lymphocytes (31). NFAT luciferase
activity was not observed. Thus, the inhibitory effect of N1L is
specific to the NF-B and not the AP-1 pathway. In separate
experiments, no cytotoxicity was evident in N1L-transfected
cells based upon Annexin V staining or flow cytometric analysis
(data not shown). Overall, these data indicate that N1L specif-
ically down-modulates signaling by NF-B that occurs in re-
sponse to several inflammatory cytokines.
N1L Inhibits Signaling to NF-B by Toll Receptors TLR2,
TLR3, and TLR4—The hypothesis that N1L inhibits Toll re-
ceptor signaling was considered for several reasons. First, N1L
possesses sequence similarity to vaccinia virus inhibitors of
toll-like receptor (TLR) signaling (2). Second, N1L inhibits
IL-1 signaling (Fig. 1A), suggesting that N1L may interact
with a component of the Toll/IL-1 signaling pathway. Finally,
whereas N1L does not appreciably inhibit adaptive immunity,
such as antibody response and cytotoxic T lymphocyte activity,
N1L significantly increases the ability of vaccinia virus to
overcome host defenses to initial viral challenge (18), suggest-
ing that N1L inhibits innate immunity. Therefore, we hypoth-
esized that N1L is involved in inhibition of the Toll receptors
that mediate an antiviral innate immune response.
To test whether N1L inhibited NF-B activation by TLR2,
TLR3, or TLR4, we used two different approaches: a ligand-de-
pendent system utilizing stable transfection of HEK 293 cells
and a transient, constitutively active TLR expression system.
HEK 293 cells stably expressing either TLR2, TLR3, or TLR4
were treated with their respective ligands: lipopeptide, the
dsRNA mimetic, poly(dIdC), or bacterial lipopolysaccharide
(LPS) (8, 32, 33) and analyzed as in Fig. 1. Chimeric versions of
the TLRs, comprising the murine CD4 extracellular domain
fused to the cytoplasmic domain of a given human TLR, have
proved useful in probing TLR signaling pathways (34). Some
TLR cytoplasmic domains can induce gene expression as ho-
modimers (TLR4 and TLR5), whereas others signal as het-
erodimers (TLR1, TLR2, and TLR6) (35). The extracellular
domain of CD4 renders the TLR chimera constructs constitu-
tively active. Using these chimeras, TLR signaling can be ex-
amined in the absence of an exogenous activator.
Signaling by TLR2 was first analyzed in stable HEK 293
transfectants. N1L inhibits TLR2-dependent signaling in re-
sponse to lipopeptide agonists (Fig. 2A, top panel, p  0.0014
for unpurified LPS, p  0.044 for membrane macrophage-
activating lipopeptide of 2 kDa). Use of transient co-transfec-
tion of N1L and constitutively active chimeric CD4-TLR1, CD4-
TLR2, CD4-TLR4, and CD4-TLR 6 demonstrates N1L-
mediated inhibition of TLR2 signaling in conjunction with
TLR1 (Fig. 2A, middle panel, p  0.0246) or TLR6 (Fig. 2A,
bottom panel, p  0.0017).
FIG. 1. N1L inhibits signaling by IL-1, TNF, and the lympho-
toxin LIGHT. A, HEK cells were co-transfected with NF-B-luciferase
and Renilla-luciferase reporters and 0, 50, or 100 ng/well N1L. At 24 h
following transfection, cells were stimulated with 10 ng/ml IL-1,
LIGHT, or TNF- for 4–6 h. Luciferase activity was measured as
described before (2) in triplicate wells in three separate experiments.
Results were normalized to Renilla luciferase intensity in the same well
and are expressed as a ratio to the lowest relative luminescence unit
value. These results are representative of at least four individual ex-
periments. B, N1L does not inhibit AP-1 luciferase activity. HEK 293
cells were transfected with one of three reporter constructs: NF-B
luciferase (NF-B), AP-1 luciferase (AP-1), or NFAT luciferase (NFAT).
Constructs were co-transfected with Renilla luciferase and either
empty vector or BZLF1 and analyzed as above. These results are rep-
resentative of three individual experiments.


























TLR3, which is known to interact with viral dsRNA, was
analyzed next. The TLR3 ligand poly(dIdC) was used to stim-
ulate stable TLR3 transfectants. 12-fold inhibition by N1L of
HEK 293 cells stably expressing TLR3 was observed (Fig. 2B,
top panel, p  0.0004). N1L inhibits signaling induced by
poly(dIdC) treatment of HEK cells transiently transfected with
FIG. 2. N1L inhibits signaling by several Toll receptors. A, N1L inhibits TLR2-dependent signaling in response to lipopeptide agonists.
HEK 293 cells transfected with TLR2 were transiently co-transfected with luciferase reporters as above, and N1L or control vector. At 24 h
following transfection, cells were stimulated with the indicated ligands. 6 h later luciferase activity was assayed as above. Middle panel, N1L
inhibits signaling by transiently co-transfected, constitutively active chimeric CD4-TLR1 and CD4-TLR2. Bottom panel, N1L inhibits signaling by
transiently co-transfected CD4-TLR1 and CD4-TLR6. These results are representative of three independent experiments. B, N1L inhibits
stimulation of stable TLR3 transfectants with poly(dIdC). In five independent experiments, HEK 293 cells stably transfected with TLR3 were
transfected with N1L and luciferase reporters, stimulated with the indicated ligand, and analyzed 18 h later as above. Bottom panel, N1L inhibited
signaling induced by poly(dIdC) treatment of HEK cells transiently transfected with TLR3. These results are representative of three independent
experiments. C, N1L inhibits the response of TLR4 transfectants to LPS. Top panel, HEK 293 cells transfected with TLR4/MD2 were transfected
with N1L and luciferase reporters, stimulated with the indicated ligand, and analyzed 18 h later as above. Bottom panel, signaling by transiently
co-transfected CD4-TLR4 was inhibited by N1L. These results are representative of three independent experiments.


























TLR3 (p  0.0174) (Fig. 2B, bottom panel). TLR4 function was
next examined and is inhibited by N1L (Fig. 2C, top panel, p 
0.011). CD4-TLR4 signaling is inhibited by N1L (p  0.0146)
(Fig. 2C, bottom panel). Given that N1L inhibits signaling by
all Toll receptors tested, one logical candidate for inhibition by
N1L was the TIR adapters that transduce signals from Toll,
IL-1, and IL-18 receptors (4, 36).
Signaling to NF-B by TIR Adapter Molecules Is Inhibited by
N1L—To identify the mechanism whereby Toll, IL-1, TNF-
and lymphotoxin signal transduction pathways are inhibited
by N1L (Fig. 1), we studied the effect of N1L upon membrane-
proximal components of the Toll/IL-1R signaling pathways
such as Mal/TIRAP, TRIF/TICAM-1, MyD88 (7–11) and TRAM
(5, 6) (Fig. 3A). Signaling via TRIF/TICAM-1 is especially rel-
evant to innate immunity against vaccinia virus since muta-
tions in TRIF are associated with a 20-fold rise in vaccinia
virus production in infected macrophages (37). N1L inhibits
TRAM and MyD88 activation of NF-B 4-fold, which is signif-
icant (p  0.002). N1L inhibits Mal/TIRAP and TRIF activation
of NF-B by 6-fold (Fig. 3A, p  0.005). In general, the N1L-
induced inhibition of the TIR adapters is comparable, suggest-
ing that a common signaling component downstream in the
Toll/IL-1R signaling pathway might be inhibited. This sug-
gested the hypothesis that TRAF family members or compo-
nents of the IKK complex might be targeted by N1L. This
hypothesis that the IKK complex is the target of N1L is con-
sistent with the fact that TIR-independent signaling, such as
signaling induced by TNF and lymphotoxins, is inhibited by
N1L (Fig. 1A).
NF-B Signaling by TRAF2 and TRAF6 Is Inhibited by
N1L—Signals initiated by pro-inflammatory cytokines or Toll
receptor engagement lead to the activation of a family of serine/
threonine kinases, the IRAK family, and TRAF6, ultimately
activating the I-B kinase (IKK) complex and leading to NF-B
translocation (15). Furthermore, because of the known interac-
tion between A52R and TRAF6 (27) and because N1L has
sequence similarity to vaccinia A52R, functional interactions
between N1L and TRAF6 were examined next.
Fig. 3B demonstrates that signaling by ectopic overexpres-
sion of TRAF2 or TRAF6 is inhibited by N1L. In Fig. 3B, 4-fold
inhibition of TRAF6 signaling and a 5-fold inhibition of TRAF2
signaling were observed, which is significant (p  0.0002 and
p  0.05, respectively). Although it is formally possible that
N1L individually targets both TRAF2 and TRAF6 for inhibi-
tion, the data of Fig. 3 suggest that inhibition by N1L may
occur downstream of these TRAF proteins.
NF-B Signaling by TBK1, IKK-, and IKK- Is Inhibited by
N1L—Several lines of evidence pointed to the IKK complex as
being central to the function of N1L. Signaling by IL-1,
TNF-, Toll, and LIGHT converged at the IKK complex and
was inhibited by N1L (Figs. 1 and 2). Furthermore, both IKK-
and IKK- signal downstream of the distinct TRAF2 and
TRAF6 signaling pathways, which are inhibited by N1L (Fig.
3). Finally, viral modulation of signaling by the IKK complex
occurs via the adenovirus 14.7-kDa protein (38), which was
reported to be similar to N1L (18).
To test the hypothesis that N1L-mediated inhibition of
NF-B signaling occurs at (or distal to) the IKK complex itself,
ectopic overexpression of IKK- and IKK- was performed in
FIG. 3. TIR adapter and TRAF signaling are inhibited by N1L.
A, NF-B signaling of the TIR adapters MyD88, TRIF, TRAM, and Mal
is inhibited by N1L. Several TIR adapters, TRIF, TRAM, MyD88, and
Mal/TIRAP, were separately co-transfected with NF-B luciferase, Tk-
Renilla luciferase reporters, and N1L or control empty vector (EV) into
HEK 293 cells. At 24 h following transfection, luciferase activity was
assayed in the cell lysates (2). Results with MyD88 and Mal are repre-
sentative of at least five independent experiments, whereas results
with TRIF and TRAM are representative of at least three independent
experiments. B, induction of NF-B signaling by TRAF2 and TRAF6 is
inhibited by N1L. TRAF2 and TRAF6 cDNAs were separately co-trans-
fected with luciferase reporters as above. NF-B activation was meas-
ured as above in the presence or absence of co-transfected N1L. N1L
inhibited NF-B activation induced by TRAF2 and TRAF6 in three
independent experiments.
FIG. 4. N1L inhibits NF-B activation by TBK1, IKK-, and
IKK-. A, cDNAs encoding IKK- and IKK- were separately co-trans-
fected with N1L into HEK 293 cells with luciferase reporters and
analyzed as above. N1L inhibited NF-B activation induced by ectopic
expression of IKK- and IKK- in at least five independent experi-
ments. B, cDNAs encoding IKK- and TBK1 were transfected with N1L
or vector control and analyzed as above. N1L inhibited NF-B activa-
tion induced by ectopic expression of TBK1 and IKK- in three inde-
pendent experiments.


























cells transfected with N1L or empty vector (Fig. 4A). The func-
tion of IKK- and IKK- is significantly inhibited by N1L (Fig.
4A, p  0.02 for IKK- and p  0.0066 for IKK-). Two related
kinases, IKK (also designated IKK-i) and TANK-binding ki-
nase 1 (TBK1) (alternatively designated NAK and T2K), have
been found to be part of a multiprotein complex that also
contains IKK-, IKK-, IKK-, and the TRAF family member-
associated NF-B activator, TANK (39). The ability of N1L to
inhibit these kinases was tested in Fig. 4B. N1L inhibits TBK1
stimulation of NF-B (p  0.003) and IKK (p  0.01). Thus,
N1L inhibits the NF-B stimulatory function of four kinases in
the IB kinase complex.
Co-immunoprecipitation of N1L and Certain NF-B Signal-
ing Components of the IKK Complex—Poxvirus protein A52R
physically associates with IRAK2 and TRAF6, thereby inhibit-
ing Toll and IL-1 signaling (27). Many other inhibitors of the
TLR and IL-1R pathway physically associate with the compo-
nents that they inhibit (4, 32). Because N1L inhibited NF-B
signaling components at and/or upstream of the IKK complex
(Figs. 2–4), we tested for a physical association between N1L
and components of the IKK complex such as IKK- and IKK-
(Fig. 5A). Two related kinases, IKK and TBK1, have also been
shown to be part of the IKK complex (39). Therefore, we also
examined the interactions of N1L with IKK and TBK1 (Fig. 5,
B and C).
To identify which kinases of the IKK complex associated with
N1L, a 6HN-tagged N1L fusion protein was co-expressed in
HEK cells with several FLAG-tagged components of the NF-B
signal transduction system. Immunoprecipitation by anti-
6HN antibody and immunoblot with anti-FLAG antibody was
performed, which revealed an association between N1L and
IKK- and IKK- (Fig. 5A, top panel). The bottom panel is an
anti-HN blot of the lysates used in the immunoprecipitation,
and it demonstrates approximately equal loading of HA-
N1LHN-tagged protein. Thus, Fig. 5A indicates that N1L can
co-immunoprecipitate IKK- and IKK-. When the same lysate
was immunoprecipitated with anti-FLAG antibody, only a min-
imal amount of N1L fusion protein was detected, suggesting
only a minimal association between IKK- and IKK- on the
reverse immunoprecipitation (data not shown).
TBK1 and IKK co-immunoprecipitate with N1L (Fig. 5, B
and C). Because the association between N1L and TBK1 occurs
whether either N1L or TBK1 is the protein being immunopre-
cipitated, these interactions in the immunoprecipitations pro-
vide further evidence that N1L and TBK1 are specifically as-
sociated. Fig. 5 suggests an association between N1L and
components of the IKK complex. IKK- and IKK- have been
shown to form a large complex with IKK, TBK1, TANK, and
members of the TRAF family. IKK- forms an oligomeric struc-
ture with IKK- and IKK- (40), associating with TANK, and
thereby, TBK1 and IKK (39). Furthermore, several other viral
proteins that modulate signaling to NF-B specifically target
IKK-. Therefore, we examined interactions between N1L and
IKK- (Fig. 6A). Fig. 6A indicates that HA-IKK- and HA-
TANK co-immunoprecipitate with N1L.
Because HA-IKK- co-immunoprecipitates with N1L, we
considered whether N1L might disrupt the association of
IKK- with IKK-/ by binding to sites common to their point
of physical association. Peptides containing a C-terminal motif
of IKK-/, which is required for IKK- binding, have been
shown to disrupt formation of IKK-IKK-/ complexes (41).
Thus, another hypothetical mechanism of action of N1L would
be to disrupt the association of IKK- with IKK-/. If N1L
bound IKK-/ directly at the IKK-IKK-/ binding site, for-
mation of IKKIKK-/ complexes would be inhibited. This is
not seen in Fig. 6B, where the association between IKKIKK
persists in the presence of N1L. N1L also associated with
TANK (Fig. 6A), which suggested that TANK, as well as TBK1,
might together be direct targets of N1L. Because other poxvi-
rus inhibitors target tandem members of the NF-B signaling
pathway (27), we sought to test whether N1L directly associ-
ated with TANK, TBK1, and IKK-.
In Fig. 7, protein-protein interactions are compared between
in vitro transcribed and translated N1L and either TBK1,
IKK-, and TANK. Aliquots of N1L and various IKK complex
components were incubated, subsequently immunoprecipi-
FIG. 5. N1L associates with components of the IKK signaling
complex. A, IKK- and IKK- associate with N1L. Top panel, an
N1L-HN fusion protein was co-expressed in HEK cells with FLAG-
tagged: IKK- (lane 1), IKK- (lane 2), and Mal (lane 3). Proteins
immunoprecipitated with anti-HN were detected on the blot with anti-
FLAG-antibody. The arrow at the left denotes the approximate size of
IKK- and IKK-. Control, FLAG-tagged Mal does not co-immunopre-
cipitate with N1L-6HN. The bottom panel denotes loading of the
N1L-6HN fusion protein. B, TBK1 associates with N1L. Top panel, an
N1L-HN fusion protein was co-expressed in HEK cells with FLAG-
tagged: IKK (lane 1) and TBK1 (lane 2). Proteins immunoprecipitated
with anti-HN were detected on the blot with anti-FLAG-antibody. The
arrow at the left denotes the approximate size of IKK- and TBK1.
Control, FLAG-tagged TRAF6 does not co-immunoprecipitate with
N1L-6HN. The bottom panel denotes loading of the N1L-6HN fusion
protein. C, N1L associates with TBK1. Top panel, FLAG-tagged IKK-
(lane 1), FLAG-tagged TBK1 (lane 2), and endogenous raf-1 (lane 3)
were immunoprecipitated and probed on the blot with anti-HN anti-
body. The arrow at the left denotes the size of HAN1L-6HN. The
bottom panel demonstrates the amount of N1L-6HN fusion protein in
5% of the lysate from each sample. IP, immunoprecipitation; IB,
immunoblot.


























tated, and then analyzed by SDS-PAGE. The results in Fig. 7
demonstrate a band in the N1L and TBK1 lanes at 15 kDa,
which corresponds to the anticipated size of N1L (18). This N1L
band is not present in the lanes containing in vitro translated
IKK- and TANK. In vitro translated/transcribed IKK- and
TANK are each present in the lanes as indicated by a band of
50 kDa. These data are consistent with the finding in Fig. 5
that TBK1 immunoprecipitates with N1L and N1L immuno-
precipitates with TBK1. Furthermore, signaling to NF-B is
inhibited by N1L (Figs. 1–4), and N1L inhibits NF-B signal-
ing by overexpression of TBK1 (Fig. 4B). Overall, the results of
Fig. 7 suggest that N1L directly targets TBK1 to inhibit acti-
vation of NF-B.
N1L Inhibits Signaling by the Interferon Response Path-
way—The host innate immune system responds to pathogens
via the interferon response pathway, which can be induced by
TLR3 and TLR4 signaling in response to viruses, double-
stranded RNA, and LPS (43). The TIR adapters TRIF and
TRAM have been shown to mediate signaling via the IRF3
pathway in response to dsRNA (poly(dIdC)) or LPS stimulation
of TLR3 and -4, respectively (44). The downstream kinases
involved in signaling include TBK1 (42) and IKK (6), which
phosphorylate the IRF3 transcription factor. Phosphorylation
permits IRF3 activation and translocation to the nucleus where
IRF3 binds co-ordinately with NF-B to promoters such as the
IFN- promoter driving the production of cytokines such as
IFN- (6).
The observation that N1L physically targets TBK1 and IKK
(Fig. 5) suggested the hypothesis that N1L would inhibit TIR
adapter stimulation driving the ISRE promoter. Because N1L
inhibits signaling to NF-B, we hypothesized N1L would in-
hibit the activity of promoters containing both NF-B and ISRE
elements, such as the interferon  (IFN-) promoter. To test
this hypothesis, N1L was co-transfected with plasmids encod-
ing ISRE and IFN- promoter elements driving a luciferase
construct. The top panel in Fig. 8 demonstrates N1L-mediated
inhibition of ISRE (p  0.0002) and IFN- (p  0.0046) lucif-
erase activity. The bottom panel in Fig. 8 demonstrates that
N1L inhibits IRF3 signaling induced by the dsRNA ligand,
poly(dIdC) in TLR3 expressing HEK cells (p  0.01). Taken
together these data indicate that N1L associates with the IKK
complex and that N1L inhibits NF-B and IRF3 signaling.
DISCUSSION
The virulence factor N1L down-modulates host cytokine re-
sponses and dysregulates innate immune signaling by IL-1R,
TLRs, and members of the TNF receptor superfamily. The data
presented here demonstrate that N1L functions, at least part,
by associating with, and inhibiting, the IKK complex. The
FIG. 7. N1L interacts with TBK1 in vitro. Protein-protein inter-
actions were assessed using in vitro transcribed and translated N1L
(lane 4) and either IKK- (lane 1), TANK (lane 2), or TBK1 (lane 3).
Following binding in vitro the proteins were immunoprecipitated and
then analyzed by SDS-PAGE. The arrow at the right denotes a 15-kDa
band in the N1L and TBK1 lanes. A band of 50 kDa is present in the
TANK and IKK- lanes, consistent with their molecular sizes.
FIG. 6. TANK and IKK associate with N1L. A, HEK cells were
co-transfected with either HA-TANK or HA-IKK and N1L-6HN.
Lysates were immunoprecipitated as denoted in the figure, and pro-
teins were detected with anti-HA antibody. B, IKK-IKK associations
persist in the presence of N1L. A N1L-HN fusion protein was co-
expressed in HEK cells with FLAG-IKK- or FLAG-TRAF2. Lysates
were immunoprecipitated as denoted in the figure, and proteins were
detected with anti-IKK antibody.
FIG. 8. N1L inhibits IRF3 signaling. A, N1L inhibits activation of
the ISRE and the IFN- promoter induced by transfection the TIR
adapter, TRAM. HEK cells were co-transfected with Renilla-luciferase
and either ISRE- or IFN--promoter luciferase, either 25 ng/well vector
or TRAM, and either 100 ng/well N1L-encoding plasmid, or empty
vector to a total of 200 ng/well. Luciferase activity was measured at 24 h
as described (2). Results are consistent with three experiments. B, N1L
inhibits IRF3 signaling induced by double-stranded RNA. HEK cells
stably expressing TLR3 were co-transfected with Renilla-luciferase,
ISRE-luciferase, and either 100 ng/well N1L-encoding plasmid or
empty vector to a total of 200 ng/well. Luciferase activity was measured
at 24 h as described (2). Results are consistent with three experiments.


























demonstration that N1L associated with several IKK complex
kinases provides a mechanistic explanation for the N1L-medi-
ated inhibition of NF-B-activating stimuli such as cytokines
(LIGHT, TNF-, and IL-1 in Fig. 2) or overexpression of intra-
cellular signaling components such as TRAF2, TRAF6, and the
TIR adaptors (Figs. 2 and 3). All these pathways converge on
the IKK signaling complex (23, 45, 46), which is inhibited by
N1L (Fig. 4). Because IKK- and IKK- are associated with the
large IKK multiprotein complex via their regulatory subunit
IKK- (39), IKK- and IKK- may be indirectly targeted be-
cause both kinases associate with IKK-, which physically as-
sociates with N1L (Fig. 6A). Other viral proteins have been
described that physically associate with IKK-, thereby alter-
ing signaling to NF-B (38, 47, 48).
However, several lines of evidence suggest that N1L does not
function by inhibiting the association of IKK- or IKK- with
IKK-. First, indirect evidence against N1L functioning by
association with IKK- is provided by the association of N1L
with TBK1 and IKK (Fig. 5B) and vice versa (Fig. 5C). TBK1
and IKK are linked to IKK-/ by IKK and TANK, suggest-
ing that a proportion of the IKK- remains associated with
IKK-/ in the presence of N1L. Second, N1L does not interfere
with the IKK-IKK- association (Fig. 6B), which further sug-
gests that N1L does not target IKK- directly. The limited
amount of HA-IKK associated with N1L (Fig. 6A) suggests
that N1L may target another member of the IKK-containing
multiprotein complex (39). The direct interaction of N1L with
TBK1 (Fig. 7) suggests that a principal target of N1L is TBK1.
Overall, these observations are consistent with the hypothesis
that N1L targets the IKK complex by a mechanism that may be
distinct from other viruses (38, 47, 48).
TBK1 is the IKK component that is most strongly implicated
as a target of N1L (Fig. 8). TBK1 has been shown to be involved
in activation of NF-B-dependent transcription (49–51). Most
recently a novel, TBK1-interacting IKK component, NAP-1,
has been shown to mediate NF-B activation by TBK1 via
phosphorylation of the p65 subunit of NF-B (52). However, the
role of TBK1 in NF-B activation is still unclear, because some
of the effects attributed to TBK1 deficiency cannot reproducibly
be linked to NF-B and are instead hypothesized to relate
primarily to effects on signaling by interferon regulatory factor
3 (IRF3) (42). TBK1 and IKK mediate the type I interferon
antiviral response (6, 42). The data presented here indicate
that TBK1 associates with N1L (Figs. 5B, 5C, and 7), and IKK
associates with N1L less strongly (Figs. 5B, 5C, and 7). These
findings suggested the hypothesis that, in addition to inhibit-
ing NF-B activation, N1L might also inhibit IRF3 signaling
that is mediated by TBK1 and IKK. In Fig. 8, N1L inhibits
IRF3 signaling. Future studies will be needed to further test
the hypothesis that the association of N1L with TBK1 inter-
rupts the type I interferon antiviral response that is mediated
in part by IRF3.
N1L-mediated inhibition of signaling by TNF superfamily
members is a distinct, and perhaps vital, viral immune evasion
mechanism. The lymphotoxins (LTs), LT-, LIGHT, and LT
12 (LT-), are part of the TNF superfamily (53). The activa-
tion of lymphotoxin receptors stimulates antiviral responses
(54–56), NF-B translocation (57), and lymphoid organogene-
sis. Furthermore, TNF- itself has potent antiviral effects and
can induce programmed cell death in certain virus-infected
cells (reviewed in Refs. 54 and 58). Several viral mechanisms
for avoiding immune responses mediated by TNF- have been
described (54, 58). Although certain poxviruses encode decoy
TNF- receptors, only certain decoy receptors neutralize LT-,
and no other poxviral lymphotoxin antagonist has been identi-
fied to date (59). Thus, N1L-mediated inhibition of the lympho-
toxin and TNF- antiviral pathways may influence the out-
come of poxviral infections.
Poxviral inhibitors of signaling inhibit a wider array of cellular
anti-viral genes than is possible with a single, virus-encoded
soluble decoy receptor. For example, N1L targets signaling by
IL-1, TNF-, lymphotoxins, and Toll receptors (Figs. 1 and 2).
Thus, targeting of the IKK complex identifies N1L as a unique
vaccinia virus inhibitor of certain antiviral signaling pathways.
Simultaneously, N1L is one of several poxvirus proteins that
target distinct points in the innate antiviral signaling pathway
(17, 28), all of which converge at the IKK complex. Furthermore,
N1L inhibits signaling by the innate immune pathways that
simultaneously suppress vaccinia virus replication (37) and acti-
vate the adaptive immune response (3, 4, 60). We hypothesize
that the much less virulent, yet almost equally immunogenic,
phenotype of N1L-deficient vaccinia virus (18) reflects suppres-
sion of innate immune signaling by N1L (Figs. 1–4, and 8),
resulting in increased virulence (18, 19) and an inhibited adapt-
ive immune response during wild type vaccinia virus infection in
vivo (18). Overall, identification of NF-B and IRF3 signaling
pathways as a target of N1L identifies the role of N1L as a viral
protein with novel immunomodulatory properties.
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